JAKARTA (Yosefardi) – Pharmaceutical firm PT Kalbe Farma Tbk (KBLF) predicts a flat revenue growth this year (7-9%) as global economic slowdown hit the rupiah against the US dollar.
Vidjongtius, independent director for KLBF, told reported on Monday (May 18) that the company had also revised down target for net profit growth this year to 7-9%, from initial target of 11%.
KLBF booked revenues of Rp17.3 trillion in 2014 and net profit of Rp2.06 trillion. It will pay dividend of Rp891 billion or Rp19 per share for 2014 fiscal year. The dividend payment represents 43% of net profit.
KLBF now has more than 20 subsidiaries and 9 production facilities with around 17,000 employees and 6,000 marketing and sales officers, with 70 branches across the country.